Trial Profile
An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Proof of concept
- Acronyms ATIRMA
- Sponsors Boehringer Ingelheim
- 01 Nov 2021 Results post hoc metabolomic analysis (n=40) assessing the effect of the SGLT2 inhibitor empagliflozin on the plasma and urine levels of metabolites in participants with Type 1 diabetes, specifically examining metabolites representing the tricarboxylic acid (TCA) cycle, lipid and amino acid pathways from participants in the ATIMRA trial (NCT01392560), published in the Diabetes, Obesity and Metabolism.
- 17 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.